Related Experiment Video
Updated: Aug 5, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
TNK1 is a targetable JAK-independent driver of STAT signaling and inflammation
Tania P López-Palacios1,2, Deshan Madhusanka1, Samuel M Scott1
1Department of Oncological Sciences, University of Utah, Salt Lake City, Utah 84112, USA.
Abstract:
Deregulated inflammatory signaling via STAT family transcription factors, particularly STAT1, underlies a variety of immune-related diseases, including inflammatory bowel disease. Whereas activation of STATs by JAKs via canonical receptor-driven JAK-STAT signaling is well understood, little is known about JAK-independent mechanisms of STAT activation. Here, we identify the understudied nonreceptor tyrosine kinase TNK1 as a therapeutically targetable, JAK-independent activator of STAT signaling. Using a multiomics approach, we mapped a network of TNK1 substrates associated with protein condensates and proinflammatory signaling, including STAT1. We found that TNK1, but not its sister kinase ACK1, directly phosphorylates STATs at well described STAT-activating JAK sites. In cells, TNK1-mediated STAT1 phosphorylation and activation occurs independently of JAKs. Imaging and interactomics data suggest that TNK1 interacts with STAT1 in cytosolic condensates, which likely compartmentalize TNK1-substrate interactions. We show that an intrinsically disordered proline-rich region in TNK1, which includes a 14-3-3 docking phosphorylation site, is required for the formation of kinase-active TNK1 condensates and STAT1 phosphorylation. Mutations within the proline-rich region that eliminate 14-3-3 binding increase formation of TNK1 condensates, suggesting a model in which 14-3-3 acts as a clamp that constrains the flexible PRR to inhibit condensate formation and STAT1 activation. Finally, we show that TNK1 is a targetable driver of STAT1-mediated inflammation in the gut as inhibition of TNK1 reduces active STAT1 in the colon and ameliorates colitis symptoms in mice.
Insights
TNK1 kinase activates STAT1 signaling independently of JAKs, driving gut inflammation. Inhibiting TNK1 reduces STAT1 activity and ameliorates colitis, offering a new therapeutic target for inflammatory bowel disease.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- Deregulated STAT1 signaling drives immune diseases like inflammatory bowel disease.
- Canonical JAK-STAT signaling is understood, but JAK-independent STAT activation is not.
Purpose of the Study:
- Identify novel, therapeutically targetable, JAK-independent activators of STAT signaling.
- Investigate the role of nonreceptor tyrosine kinase TNK1 in STAT activation and inflammation.
Main Methods:
- Multiomics approach to map TNK1 substrates.
- Cellular imaging and interactomics to study TNK1-STAT1 interactions.
- In vitro kinase assays and in vivo mouse models of colitis.
Main Results:
- TNK1 directly phosphorylates and activates STAT1 independently of JAKs.
- TNK1 forms cytosolic condensates with STAT1, regulated by its proline-rich region and 14-3-3 binding.
- TNK1 inhibition reduces STAT1 activity in the colon and alleviates colitis symptoms in mice.
Conclusions:
- TNK1 is a novel, JAK-independent activator of STAT1 signaling.
- TNK1-mediated STAT1 activation in cytosolic condensates drives gut inflammation.
- TNK1 represents a promising therapeutic target for inflammatory bowel disease.
Related Concept Videos
The JAK-STAT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
PI3K/mTOR/AKT Signaling Pathway
TGF - β Signaling Pathway
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...